Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Sold by Diversify Wealth Management LLC

Diversify Wealth Management LLC decreased its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) by 7.6% in the 4th quarter, Holdings Channel.com reports. The fund owned 12,385 shares of the company’s stock after selling 1,013 shares during the quarter. Diversify Wealth Management LLC’s holdings in Castle Biosciences were worth $330,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Quest Partners LLC grew its holdings in shares of Castle Biosciences by 54.4% during the 3rd quarter. Quest Partners LLC now owns 4,318 shares of the company’s stock worth $123,000 after purchasing an additional 1,522 shares during the period. US Bancorp DE boosted its stake in Castle Biosciences by 1,889.2% during the third quarter. US Bancorp DE now owns 4,615 shares of the company’s stock worth $132,000 after buying an additional 4,383 shares during the period. Point72 DIFC Ltd acquired a new stake in shares of Castle Biosciences during the third quarter valued at about $140,000. Assetmark Inc. raised its stake in shares of Castle Biosciences by 16.8% in the 3rd quarter. Assetmark Inc. now owns 5,212 shares of the company’s stock valued at $149,000 after acquiring an additional 748 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Castle Biosciences by 64.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,335 shares of the company’s stock worth $152,000 after acquiring an additional 2,093 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on CSTL. BTIG Research upped their price target on Castle Biosciences from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Scotiabank increased their target price on Castle Biosciences from $37.00 to $44.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, November 6th. Canaccord Genuity Group lifted their target price on Castle Biosciences from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, October 29th. KeyCorp raised their price objective on shares of Castle Biosciences from $28.00 to $36.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Finally, Stephens restated an “overweight” rating and issued a $41.00 price objective on shares of Castle Biosciences in a report on Thursday, January 2nd. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $40.29.

Insider Transactions at Castle Biosciences

In related news, insider Derek J. Maetzold sold 1,972 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $34.15, for a total transaction of $67,343.80. Following the completion of the sale, the insider now owns 87,720 shares in the company, valued at $2,995,638. The trade was a 2.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Daniel Bradbury sold 7,867 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $29.14, for a total transaction of $229,244.38. Following the completion of the transaction, the director now owns 1,425 shares in the company, valued at $41,524.50. This represents a 84.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 35,306 shares of company stock valued at $1,063,756. 7.20% of the stock is currently owned by corporate insiders.

Castle Biosciences Stock Down 0.4 %

Shares of Castle Biosciences stock opened at $26.62 on Thursday. The company has a quick ratio of 7.64, a current ratio of 7.78 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a 52-week low of $16.97 and a 52-week high of $35.84. The company has a market capitalization of $745.63 million, a P/E ratio of 133.11 and a beta of 0.92. The company has a 50 day moving average of $28.77 and a 200 day moving average of $28.19.

Castle Biosciences (NASDAQ:CSTL) last released its quarterly earnings data on Monday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.14. The business had revenue of $85.78 million during the quarter, compared to analysts’ expectations of $78.55 million. Castle Biosciences had a net margin of 1.95% and a return on equity of 1.47%. During the same period in the previous year, the company earned ($0.26) EPS. As a group, research analysts forecast that Castle Biosciences, Inc. will post 0.34 EPS for the current fiscal year.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.